✉news HealthMedicine first seen 1 d ago, last 1 d ago, peak #33
Disc Medicine's Bitopertin Hits Phase III Goals
Original: Disc Medicine’s Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
Disc Medicine announced that its drug bitopertin met its Phase III clinical trial endpoints, clearing the way for a planned resubmission to the US Food and Drug Administration. The results mark a key milestone for the biotech company, whose lead therapy is being developed for blood disorders, and set the stage for a potential regulatory decision in the United States.
Why now: The positive Phase III data advances the drug toward possible FDA approval, a significant catalyst for investors and patients.
Disc MedicineBitopertinUS Food and Drug Administration
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/2888505